Calmare Therapeutics Appoints Christine Chansky, M.D., J.D., F.C.L.M., Chief Regulatory Officer

FAIRFIELD, Conn.--(BUSINESS WIRE)--Calmare Therapeutics Incorporated, (OTCQB:CTTC) (CTI), the Calmare® chronic pain and wound care company, has appointed Dr. Christine Chansky, M.D., J.D., F.C.L.M., chief regulatory officer (CRO) of Calmare Therapeutics.

Suggested Articles

AstraZeneca is confident data generated across development show the antibody works despite a pivotal study missing its primary endpoint.

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.